Related references
Note: Only part of the references are listed.Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide
Lucio Tentori et al.
BMC CANCER (2014)
Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrixassociated gene modules
Rutger K. Balvers et al.
NEURO-ONCOLOGY (2013)
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome
Shadi Lalezari et al.
NEURO-ONCOLOGY (2013)
Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma
Lara Barazzuol et al.
RADIATION ONCOLOGY (2013)
Guidelines for the use and interpretation of assays for monitoring autophagy
Daniel J. Klionsky et al.
AUTOPHAGY (2012)
Advances in using PARP inhibitors to treat cancer
Shivaani Kummar et al.
BMC MEDICINE (2012)
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012
L. Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2012)
O6-Methylguanine-Methyltransferase (MGMT) Promoter Methylation Status in Glioma Stem-Like Cells is Correlated to Temozolomide Sensitivity Under Differentiation-Promoting Conditions
Claire Villalva et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients
Sameer Agnihotri et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines
Dagmar Beier et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
Elisabet Wahlberg et al.
NATURE BIOTECHNOLOGY (2012)
PARP-1 Modulation of mTOR Signaling in Response to a DNA Alkylating Agent
Chantal Ethier et al.
PLOS ONE (2012)
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Konstantin J. Dedes et al.
CELL CYCLE (2011)
Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
Dagmar Beier et al.
MOLECULAR CANCER (2011)
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
K. A. van Nifterik et al.
BRITISH JOURNAL OF CANCER (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates
Jodi A. Muscal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
Brian McEllin et al.
CANCER RESEARCH (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Raga Krishnakumar et al.
MOLECULAR CELL (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
Sensitivity to temozolomide in brain tumor initiating cells
Michael D. Blough et al.
NEURO-ONCOLOGY (2010)
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
Jason T. Huse et al.
NATURE REVIEWS CANCER (2010)
A New Model for Prediction of Drug Distribution in Tumor and Normal Tissues: Pharmacokinetics of Temozolomide in Glioma Patients
Lula Rosso et al.
CANCER RESEARCH (2009)
Genetic alterations and signaling pathways in the evolution of gliomas
Hiroko Ohgaki et al.
CANCER SCIENCE (2009)
Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic Screens
Steven M. Pollard et al.
CELL STEM CELL (2009)
ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
Joann P. Palma et al.
CLINICAL CANCER RESEARCH (2009)
Temozolomide preferentially depletes cancer stem cells in glioblastoma
Dagmar Beier et al.
CANCER RESEARCH (2008)
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Nicholas C. Turner et al.
EMBO JOURNAL (2008)
Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas
Aiguo Li et al.
MOLECULAR CANCER RESEARCH (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
Jeffrey M. Albert et al.
CLINICAL CANCER RESEARCH (2007)
ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
Cherrie K. Donawho et al.
CLINICAL CANCER RESEARCH (2007)
HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity
Virginie Clement et al.
CURRENT BIOLOGY (2007)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao et al.
NATURE (2006)
Analysis of gene expression and chemoresistance of CDI33+ cancer stem cells in glioblastoma
Gentao Liu et al.
MOLECULAR CANCER (2006)
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines
Jeongwu Lee et al.
CANCER CELL (2006)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients
S Ostermann et al.
CLINICAL CANCER RESEARCH (2004)
Poly (ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells
L Tentori et al.
GLIA (2002)
Share Paper
